Eggbaconandbubble
26 Nov 2014
Re: Upto 10 potential buyers Why ask (and pay) Rothschild to find a buyer when they purport to have been approached by so many companies already?
ArianParod
26 Nov 2014
Upto 10 potential buyers MARKET REPORT: Buyers lining up for Sinclair sale as shares rise 12% to three-year highGEOFF FOSTER FOR THE DAILY MAILPUBLISHED: 01
5, 26 November 2014 | UPDATED: 015, 26 November 2014No less than ten interested parties are believed to have shown an interest in Sinclair IS Pharma, which has put itself up for sale.Shares of the aesthetics and skincare company rose 4p or 12 per cent to a three-year high of 36.5p after it was revealed it has appointed Rothschild to explore means of realising shareholder value. In other words, find a buyer.Private equity players and Swiss food giant Nestle, which earlier this year set up a specialised medical skin care division after acquiring the rights to sell certain products in the US and Canada from Valeant Pharmaceuticals for £840million cash, are rumoured to be heading the queue of buyers willing to pay up to about £300million or 60p-plus a share for the company, which owns an anti-ageing treatment that could turn out to be better than Botox.Promising: No less than ten interested parties are believed to have shown an interest in Sinclair IS Pharma, which has put itself up for saleIt was on the cards that Sinclair would be re-rated following the recent stonking £42billion bid for Botox giant Allergan.Sinclair owns Silhouette, a company which manufactures Silhouette Soft, a £1,200 anti-ageing treatment that uses dissolvable thread to beat wrinkles. Broker N+1 Singer is bullish and says the company’s exciting product portfolio could bring substantial value to a potential acquirer.Major Sinclair shareholders include heavyweights Toscafund, Lansdowne and George Soros. He lifted his stake above 5 per cent in June by acquiring more stock at 32p a pop.
dwiggy
25 Nov 2014
Re: Patience- and here it is! Yes, might get a little pull back with RSI showing overbought and price well outside the bollinger bands but defo upward trend starting here going forwards...
II Editor
25 Nov 2014
NEW ARTICLE: Sinclair IS Pharma up for sale "Just days after appearing in Interactive Investor's feature AIM's fastest growing companies LSE:SPH:Sinclair IS Pharma has put itself up for sale. The skin-focused pharma firm has asked Rothschild to help it find a buyer for all or part of the ..."[link]
jonnydurex
25 Nov 2014
Patience- and here it is! Patience is a virtue and another 30% to come? Great news for 2015.gla jd
winningstreak
25 Nov 2014
Re: and here it is And the Directors have had a good feeling about that for quite some time, hencetheir hefty purchases (look purchases history).I reckon we shall see 40p+ before long.ws
dwiggy
25 Nov 2014
Re: and here it is Doesn't get much better than this and the institutions know it....What's not to like here
ArianParod
25 Nov 2014
and here it is TIDMSPHRNS Number : 8731XSinclair IS Pharma PLC25 November 2014NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTIONSinclair IS Pharma plc ("Sinclair" or "the Company"
AGM Statement, trading update, announcement of strategic review and commencement of offer period.Grahame Cook, Chairman of Sinclair, will make the following statement at the Company's AGM which will be held later today.Sinclair has a market leading aesthetics dermatology portfolio. We also have a significant product pipeline which includes Flammacerium that has already been granted orphan drug status in the United States. The Board of Sinclair believes the portfolio has significant and sustainable growth potential across the world.The Board of Sinclair is pleased to report that the Company continues to trade well and in line with the Board's expectations.The Board believes that industry recognition of the Company's growth prospects explains the significant attention the Company is receiving from a number of international companies, many of which are interested in some form of, co-operation, including: (co)-promotion; licensing of products; repatriation of distribution agreements; development collaborations; and merger and acquisition opportunities.As a result of the deliberation process arising out of these opportunities, the Board recognises that there may be organisations better placed to build on the successes to date.Accordingly, the Board has decided to appoint Rothschild to assist it in evaluating the optimum way to realise the considerable value in the Company which may, or may not, include the sale of all or part of the Company. The Board believes that Sinclair has a secure future as an independent business and will only engage with those willing to recognise and support the Company's significant growth potential.The UK Takeover Panel ("the Panel" has agreed that any such discussions with third parties may be conducted within the framework set out in Note 2 on Rule 2.6 of the Takeover Code (the "Code". The Panel has granted a dispensation from the requirements of Rules 2.4(a), 2.4(b) and 2.6(a) of the Code such that any interested party will not be required to be publicly identified as a result of this announcement (subject to note 3 to Rule 2.2 of the Code) and will not be subject to the 28 day deadline referred to in Rule 2.6(a), for so long as it is participating in discussions with Sinclair.
ArianParod
25 Nov 2014
We have news!!! nm
5o waw
24 Nov 2014
Re: Trades Ambiorix1, Many thanks for your in depth reply and knowledge of SPH.
Ambiorix1
23 Nov 2014
Re: Trades Hello again 50I don’t think Tosca is going to make another move. At the moment, they seem to be keeping the egg’s warm. Landsdowne Partners could increase their holding, but most probably the man behind the ‘manoeuvres in the dark’ is Stuart Swanson. I’m in no doubt he still has some funds to spend on Sinclair. The question is what he will do with his increased stake. Could he be just an intermediate link? He is leaving Sinclair to ‘spend his time’ with Amicus SA in Zug/Switzerland (partner of Sinclair for the Balkan region). Amicus SA is most probably just a new name for former PharmaSwiss. In the ‘SHAB Meldungen’ you can find under Amicus SA : statute datum 05.11.2013. and ‘eingetragene person’ : Kosir Barbara. Mrs Barabara Kosir has been assistant CFO of former PharmaSwiss. And who could come over from time to time to have a chat with Barbara. Maybe Andreas Wicki, former director of PharmaSwiss and actually one of the men in power at HBM bioventures. And this link is even more interesting if you now that HBM is main shareholder of SkyePharma. One of the directors of SKP is our own Jean-Charles Tschudin. And who has been buying a lot of Sinclair shares lately? Indeed Jean-Charles. This could tidily close the circle. If so, I would not be surprised HBM Bioventures or one of the firms it controls (Basilea, Pacira) absorbs Sinclair. All I hope for is that they pay a decent price for it to the remaining small shareholders who waited long enough to be rewarded. Ambiorix.
5o waw
23 Nov 2014
Re: Trades I have never understood why Tosca built up their holding to 29+% and stopped i.e. 30+% they would have to make a bid at the highest s/p over the last 12 months. Just maybe the 16m missing shares are heading there? IMHO.
Ambiorix1
23 Nov 2014
Re: Trades Good question 50 Waw,I made the same remark to myself. I had a look at the digitallook website to get the latest numbers on major shareholdings and according to this site, AXA held more than 42 million shares. In their latest RNS AXA mentions they don’t hold any Sinclair shares anymore. Since they sold some 27 million shares, there seems to have been a serious number of shares sold before this last sale. I didn’t see any RNS mentioning this. And then there is this strange move from Henderson. One day they mention a substantial direct holding and just a day later the biggest part of this holding is exchanged as CFD’s. Is somebody betting on a substantial rise very soon?Ambiorix.
5o waw
23 Nov 2014
Re: Trades Nice to see the share price moving North last week AXA sold Henderson bought but where has the missing 16m shares gone? Someone I feel bought them according to the trades.
dwiggy
19 Nov 2014
Re: Trades Henderson the culprit...
